TMCnet News
AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019CAMBRIDGE, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and investor presentation and webcast scheduled for Wednesday, February 6, 2019, at which time the Company will provide clinical trial updates related to its investigational gene therapy program for AVR-RD-01 in Fabry disease. The Company’s presentation and webcast is now scheduled to start at 5:30 p.m. ET on Wednesday, February 6, 2019. For analysts and investors attending in person, an informal reception that starts at 5:00 p.m. ET will precede the presentation and webcast. The Company’s presentation and webcast will be held in conjunction with WORLDSymposium, an annual conference dedicated to lysosomal diseases, being held February 4-8, 2019 in Orlando, Florida. A live webcast of the presentation and accompanying slides will be available under “Events and Presentations” in the Investors section of the Company’s website at www.avrobio.com. An archived webcast recording of the event will be available on the website for approximately 30 days. About AVROBIO, Inc. Forward-Looking Statements Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any of AVROBIO’s ongoing or planned clinical trials, the risk that AVROBIO may not realize the intended benefits of efforts to optimize its platform, and the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO’s product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in AVROBIO’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO’s subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Investor Contact: Christopher F. Brinzey Westwicke Partners 339-970-2843 [email protected] Media Contact: Kathryn Morris The Yates Network 914-204-6412 [email protected] |